Cardiovasc Diabetol: Efficacy and safety of GLP-1 agonists versus SGLT-2 inhibitors in type 2 diabetes

Background: Cardiovascular outcome trials (CVOTs) conducted in patients with type 2 diabetes mellitus (T2D) over the past few years have shown that GLP-1 agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) reduce the risk of

Recent guidelines recommend starting GLP-1 RA or SGLT-2i in patients at high cardiovascular risk or in patients with confirmed atherosclerotic cardiovascular disease, regardless of baseline glycosylated hemoglobin levels

Objective: In this study, we analyzed the efficacy and safety

Methods: Using a linkable managed health database, we included patients aged 50 years and older who

Results: The analysis included 20,762 patients

Figure 1 matches the number of events and the risk-to-risk ratio of death and clinical outcomes in the population according to treatment status (CI 95%) (ITT analysis

Figure 2: Event number and risk ratio of deaths and clinical outcomes in a matched population without prior cardiovascular disease (CI 95%)

Table 1 Number of events and risk ratios of people matching deaths and clinical outcomes according to treatment status (PP analysis) (CI 95%)

Table 2 Frequency of serious adverse events by treatment status from 2015 to 2019

GLP-1RA has shown to be as secure and more effective

Source: Baviera M, Foresta A, Colacioppo P,et al.